# Core C: Cell Processing and Sample Collection

> **NIH NIH P01** · FRED HUTCHINSON CANCER CENTER · 2022 · $120,699

## Abstract

PROJECT SUMMARY/ABSTRACT
Cell Processing and Sample Collection: Core C
This FHCRC Adult Leukemia Research Center (ALC) grant comprises proposals for three clinical trials: one
trial of adoptive immunotherapy with WT1-specific T cell receptor (TCR) gene-modified T cells for acute
myeloid leukemia (Project 1); one trial of adoptive immunotherapy using BCMA-specific chimeric antigen
receptor (CAR)-modified T cells for multiple myeloma (Project 2); and one trial comparing methods of T cell
depletion of donor grafts for allogeneic HCT (Project 3). Core C: Cell Processing and Sample Collection will
support the activities of Projects 1-3. First, Core C will provide highly specialized facilities and expertise
necessary to conduct current Good Manufacturing Practice (cGMP) production of TCR- and CAR-modified T
cells for Projects 1-2 for treatment of patients enrolled in the clinical trials proposed in Projects 1-2. This effort
will initially comprise validation cell processing runs (years 1-2) to qualify standard operating procedures for
subsequent cGMP production, followed by cGMP production and release of genetically modified T cell
products (years 1-5). Compared to decentralized cell processing managed by each separate project,
consolidation of clinical cell processing within Core C will ensure that cGMP manufacturing is efficient and
cost-effective, and performed with the optimal level of quality control (QC) and quality assurance (QA)
oversight. Second, Core C will conduct studies to evaluate the effects of short-term storage in infusion medium
or of cryopreservation on the potency of CAR- or TCR-modified T cells for clinical use. Although the potency of
genetically modified T cells that are freshly formulated may be better than that of those that are stored, the
ability to store and cryopreserve these products will be important for clinical logistics and for future delivery
beyond phase 1 studies. We will conduct these studies using models in which human genetically modified T
cells that have been stored under different conditions are administered to immunodeficient mice bearing
human tumors, because we have found that data in these models of efficacy most accurately reflects
outcomes in human engineered T cell clinical trials. Because the manufacturing processes may affect the
capacity of genetically modified T cell products to tolerate storage, we will conduct these experiments using T
cells that are manufactured using either a process involving multiple in vitro stimulations (Project 1) or a
truncated process involving only a single stimulation (Project 2). The data will provide insight into whether
important and frequently performed processing manipulations affect potency of genetically modified T cells.
Third, Core C will provide a clinic-based facility to rapidly and efficiently process and distribute research
samples from Projects 1-3 to FHCRC research laboratories and external collaborators. This will ensure data of
the highest quality and u...

## Key facts

- **NIH application ID:** 10412944
- **Project number:** 5P01CA018029-47
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** Cameron John Turtle
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $120,699
- **Award type:** 5
- **Project period:** 1997-08-28 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10412944

## Citation

> US National Institutes of Health, RePORTER application 10412944, Core C: Cell Processing and Sample Collection (5P01CA018029-47). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10412944. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*